Gamble Jones Investment Counsel decreased its position in shares of Danaher Co. (NYSE:DHR) by 25.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,115 shares of the conglomerate’s stock after selling 1,410 shares during the quarter. Gamble Jones Investment Counsel’s holdings in Danaher were worth $594,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Bingham Osborn & Scarborough LLC purchased a new stake in Danaher in the 3rd quarter valued at approximately $237,000. Bourgeon Capital Management LLC lifted its stake in Danaher by 0.4% in the 3rd quarter. Bourgeon Capital Management LLC now owns 55,684 shares of the conglomerate’s stock valued at $8,042,000 after buying an additional 230 shares in the last quarter. Alps Advisors Inc. lifted its stake in Danaher by 193.0% in the 3rd quarter. Alps Advisors Inc. now owns 36,455 shares of the conglomerate’s stock valued at $5,265,000 after buying an additional 24,012 shares in the last quarter. SG Americas Securities LLC lifted its stake in Danaher by 179.3% in the 3rd quarter. SG Americas Securities LLC now owns 561,470 shares of the conglomerate’s stock valued at $81,093,000 after buying an additional 360,427 shares in the last quarter. Finally, First Trust Advisors LP lifted its stake in Danaher by 52.7% in the 3rd quarter. First Trust Advisors LP now owns 383,174 shares of the conglomerate’s stock valued at $55,342,000 after buying an additional 132,166 shares in the last quarter. 78.30% of the stock is currently owned by institutional investors and hedge funds.
DHR has been the topic of a number of recent research reports. Robert W. Baird upped their target price on Danaher from $131.00 to $148.00 and gave the company an “outperform” rating in a research note on Friday, July 19th. Needham & Company LLC reduced their target price on Danaher from $155.00 to $152.00 and set a “buy” rating on the stock in a research note on Monday, October 28th. Piper Jaffray Companies boosted their price target on Danaher from $148.00 to $153.00 and gave the company a “neutral” rating in a report on Thursday, July 18th. Royal Bank of Canada set a $134.00 price target on Danaher and gave the company a “hold” rating in a report on Friday, July 19th. Finally, Credit Suisse Group reiterated an “outperform” rating and issued a $151.00 price target on shares of Danaher in a report on Monday, October 14th. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $145.86.
Danaher (NYSE:DHR) last issued its quarterly earnings results on Thursday, October 24th. The conglomerate reported $1.16 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.15 by $0.01. The company had revenue of $5.04 billion during the quarter, compared to the consensus estimate of $5.02 billion. Danaher had a return on equity of 11.42% and a net margin of 12.13%. Danaher’s revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.10 EPS. Equities analysts anticipate that Danaher Co. will post 4.76 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a dividend of $0.17 per share. The ex-dividend date was Thursday, September 26th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.50%. Danaher’s payout ratio is 15.04%.
In other news, Chairman Mitchell P. Rales acquired 2,500 shares of the company’s stock in a transaction dated Friday, August 23rd. The stock was acquired at an average cost of $139.52 per share, for a total transaction of $348,800.00. Following the acquisition, the chairman now directly owns 3,030,453 shares in the company, valued at approximately $422,808,802.56. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 11.40% of the company’s stock.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Featured Article: Understanding the different types of bonds
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.